Antiretroviral and immunosuppressive drug-drug interactions: An update  by Izzedine, Hassane et al.
Kidney International, Vol. 66 (2004), pp. 532–541
PERSPECTIVES IN RENAL MEDICINE
Antiretroviral and immunosuppressive drug-drug interactions:
An update
HASSANE IZZEDINE, VINCENT LAUNAY-VACHER, ALAIN BAUMELOU, and GILBERT DERAY
Department of Nephrology, Pitie´ Salpeˆtrie`re Hospital, Paris, France
Antiretroviral and immunosuppressive drug-drug interactions:
An update. With the introduction of highly active antiretrovi-
ral therapy (HAART), human immunodeficiency virus (HIV)
infection has become a chronic disease with more frequent
end-stage organ failures. As a result, the question of trans-
plantation in HIV patients is raised more often. However,
some of the HAART regimen medications require elimination
or metabolism via the P-glycoprotein (P-gp) and multidrug-
resistant protein (MRP) transporters or via the cytochrome
P450 enzyme system. Since these transporters and enzymes
are also responsible for the clearance of immunosuppressive
drugs, drug-drug interactions are likely to occur. Indeed, pro-
found drug-drug interactions between protease inhibitors and
immunosupressive drugs have been observed and they required
reductions in drug dosage. In contrast, HAART using nucleo-
side or nonnucleoside reverse transcriptase inhibitors without
the use of protease inhibitors has been shown to produce less
significant drug-drug interactions. It is thus crucial to take into
account those potential pharmacokinetic and/or pharmacody-
namic drug-drug interactions in order to avoid drug toxicity or
a lack of efficacy. The aim of this work was to review and syn-
thesize the international literature on this field in order to give
practical recommendations on how to manage immunosupres-
sive drugs in HIV patients who get transplanted and on how to
handle HAART therapy in transplant-recipient patients who
get infected with HIV.
Patients with human immunodeficiency virus (HIV) in-
fection have been traditionally excluded from consider-
ation for solid organ transplantation. However, highly
active antiretroviral therapy (HAART) has changed the
natural history of HIV infection by improving immune
function in HIV-infected individuals [1]. As a result,
there are now potentially more deaths from end-stage or-
gan disease rather than acquired immunodeficiency syn-
drome (AIDS)-associated opportunistic infections and
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neoplasms. Consequently, the use of new therapeutic av-
enues, such as solid organ transplantation and stem cell
transplantation, may be considered in patients with HIV
infection [2, 3]. Indeed, solid organ transplantations have
been performed successfully in selected HIV+ patients
with HAART. Although many questions about HIV and
transplantation remain unanswered, enough data exist
to warrant reconsideration of HIV disease in transplan-
tation [4].
Mechanisms of drug-drug interaction are various and
complex. Most often they include competitive interac-
tion between two drugs that are metabolized via the
same enzyme system such as cytochrome P450 (CYP),
the most popular of which is CYP3A4. Drug-drug inter-
action may also result from a competition between two
drugs that are substrates for the same active transport
system. Such cellular transporters include P-glycoprotein
(P-gp), multidrug-resistant protein (MRP1, and MRP2),
most often. In addition to these competitive mechanisms,
some drugs may also exhibit inhibiting or inducing activ-
ities on the expression and/or the activity of CYP and
transporters. When associated to substrates of these sys-
tems, those drugs may induce metabolic and/or excretion
alterations that would result in significant pharmacoki-
netic and pharmacodynamic changes.
The aim of this review was thus to examine the extent of
potential drug-drug interactions between antiretroviral
and immunosuppressive agents.
CLINICAL DATA FROM SOLID ORGAN
TRANSPLANTATION IN HIV PATIENTS
During the pre-HAART period
Little is known on the outcomes of solid organ trans-
plantation in HIV+ recipients from the pre-HAART era.
Some data suggest that solid organ transplantation in
the pre-HAART period was associated with outcomes
that were suboptimal, but certainly not dismal [4]. Pa-
tient and graft 3-year survival were significantly reduced
in HIV+ recipients (53% graft and 83% patient sur-
vival) compared to the United States Renal Data System
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(USRDS) population (73% and 88%, respectively) [5].
Furthermore, accidental transmission of HIV to trans-
plant recipients with organs or blood products and im-
mune suppression for transplantation in the pre-HAART
era was generally associated with an accelerated course
of AIDS [6]. Erice et al [7] reported that in a cohort
of 88 transplant patients, 25 (28%) of them developed
AIDS. Twenty (80%) of these 25 patients died of AIDS-
related complications after a mean 37 months after trans-
plantation. The mean time of progression to AIDS was
27.5 months among those patients. For patients who were
negative for HIV at the time of transplantation, the mean
time of progression to AIDS after HIV infection was
32 months, whereas patients who were HIV+ be-
fore transplantation developed AIDS within 17 months.
Shortly after transplantation, 11 patients (12.5%) who
were initially seronegative experienced a febrile syn-
drome attributed to HIV. Ten patients, including eight
recipients of kidney transplants and two recipients of
liver transplants, maintained normal allograft function
with low-dose immunosuppressive therapy.
Clinical outcomes of solid organ transplant
in the HAART period
In the United States, mortality among AIDS patients
decreased from 29.4% patient-years in 1995 to 8.8%
patient-years in 1997. Similarly, the incidence of oppor-
tunistic infections (Pneumocystis carinii pneumonia and
cytomegalovirus retinitis) decreased from 21.9% patient-
years to 3.7% patient-years. At the same time, the num-
ber of HIV+ patients undergoing dialysis continued to
increase, from 1.5% in 1994 to 15% in 1996. According
to USRDS, AIDS and HIV are listed as comorbidities for
0.4% and 0.7% of the total dialysis population in 1999,
respectively. AIDS- or HIV-infected patients thus consti-
tute a growing number of potential candidates for kidney
transplantation [4].
Data on outcome are lacking regarding liver and/or
kidney transplantation in HIV+ patients in the HAART
era.
Stock et al [8] reported 14 patients who received trans-
plants (ten kidney transplants, mean follow-up 480 days;
four liver transplants, mean follow-up 380 days). They
had undetectable plasma HIV-1 RNA levels (viral load)
for 3 months (kidney) or were predicted to achieve vi-
ral load suppression posttransplantation if unable to tol-
erate HAART (liver), a CD4+ T-cell count of more
than 200 cells/lL (kidney) or more than 100 cells/lL
(liver) for 6 months, and no history of opportunistic in-
fections or neoplasm. Standard immunosuppression in-
cluded prednisone, mycophenolate mofetil (MMF), and
cyclosporine. At 240 days posttransplantation, all kidney
transplant recipients (100%) were alive and with func-
tioning grafts, and three of four liver transplant patients
(75%) are alive and well with functioning grafts (all liver
transplant patients with normal liver function tests). The
one death occurred 445 days posttransplantation in a liver
recipient coinfected with hepatitis C virus, who died as
the result of its rapid reoccurrence. Rejection occurred
in 5 of 10 kidney transplant recipients but did not occur
in any of the four liver transplant recipients. HIV viral
loads remained undetectable in all patients maintained
with HAART. CD4 counts remained stable in patients
not treated for rejection. Patients receiving protease
inhibitors require 25% of the dose of cyclosporine as
compared with patients receiving nonnucleoside reverse
transcriptase inhibitors [8]. Toso et al [9] reported a
case of combined kidney-pancreas transplantation in an
HIV-infected patient. The patient’s HIV remained stable
without any antiviral therapy and grafted organs demon-
strated good function without rejection for 2 years after
transplantation. This case emphasizes the need to con-
sider long-term nonprogressor HIV patients as a specific
subgroup when discussing solid organ transplantation.
This subgroup of HIV patients should be offered less re-
stricted access to transplantation. Neff et al [10] evalu-
ated the survival of patients undergoing orthotopic liver
transplantation (OLT) with HIV under HAART ther-
apy. OLT was performed in 16 patients with HIV suf-
fering from end-stage liver disease as a result of chronic
hepatitis C virus, chronic hepatitis B virus, or fulminant
hepatic failure. Of the 16 patients who received OLT,
14 remain alive. Thirteen of the 16 patients were more
than 12 months post-OLT, whereas the last patient was at
6 months post-OLT when the study was reported. Most
patients received HAART therapy before OLT. Thus,
patients had their HAART therapy discontinued before
OLT because of significant liver dysfunction. The pre-
OLT viral loads were undetectable in 13 of 16 patients.
The cluster determinant CD4 count was less than 200 in
six patients and greater than 100 in two patients before
OLT. In all patients, CD4 counts increased above 200 in
the post-OLT period. Tacrolimus toxicity associated with
the pharmacologic inhibition of CYP metabolism caused
by protease inhibitors occurred in six patients after OLT.
Six patients (38%) experienced acute cellular rejection
immediately after OLT.
In a recent study of 45 HIV-infected recipients of kid-
ney or liver transplants, outcomes in the subgroup of 23
patients with at least 1 year of follow-up were in the
range of those reported by the United Network for Or-
gan Sharing for more than 45,000 patients. In the period
after transplantation, there were only two opportunistic
complications, CD4+ T-cell counts remained stable and
HIV RNA levels in plasma were suppressed. No patients
with a history of opportunistic infections or with a CD4
cell count below 200 per mm3 before kidney transplan-
tation or below 100 per mm3 before liver transplanta-
tion were included. In addition, it was expected that, with
534 Izzedine et al: Antiretroviral and immunosuppressive drug-drug interactions
antiretroviral therapy, HIV suppression after transplan-
tation would be achievable in all of them [11, 12].
Calabrese et al [13] reported a case of a heart trans-
plant in an HIV-1–infected recipient who was doing well
2 years after transplantation. From 1992 to 1995, he was
exclusively treated with nucleoside analogues in varying
combinations of zidovudine, lamivudine, and stavudine.
Protease-inhibitor–based therapy was initiated in June
1995, with ritonavir, added to a stable regimen of zi-
dovudine and lamivudine. In January 2001, the patient
was evaluated for possible cardiac transplantation. Im-
munosuppressive therapy after transplantation included
glucocorticoids, calcineurin antagonists, and antimetabo-
lites. The clinical course has been marked, however, by
frequent episodes of rejection (ranging from grade 0 to
grade 3A). Treatment of these episodes consisted of glu-
cocorticoid boluses. In addition, the dose of prednisone
has been tapered much more gradually than usual. Be-
cause of the clinical success of the patient’s therapy, it was
decided that ritonavir therapy should be continued and
that pharmacokinetic modeling should be undertaken to
address the major adjustments required in the dose of
cyclosporine. With dramatic reductions in the dose of
cyclosporine based on this modeling, drug levels have
nonetheless been a matter of concern. Despite the use
of a dose of 25 mg once daily, whole-blood trough cy-
closporine levels have remained in the range of 198 to
531 ng/mL, and the most recent measurement of serum
creatinine concentration was 2.7 mg/dL [13].
Fung [14] described four HIV-infected patients who
had undergone renal transplantation. The patients did
not progress to AIDS (CD4 <200 cells/mm3) and main-
tained undetectable viral loads (less than 50 copies/mL)
at 1, 1, 2, and 3 years following transplantation, respec-
tively. Three patients were weaned off corticosteroids
and maintained serum creatinine concentrations of 1.2 to
1.6 mg/dL. One patient had “moderate to severe” rejec-
tion with a functioning graft (serum creatinine concentra-
tion 2.5 to 3 mg/dL). All four patients were alive at 1, 1, 2,
and 3 years, respectively. A prospective study conducted
by centers in San Francisco and Philadelphia [15] showed
similar results. Among 12 HIV-infected patients who un-
derwent renal transplantation, a 100% patient and graft
survival was observed at 1 year. Recent data from the
same group of investigators, regarding 23 patients from
eight transplant centers across the United States, were
presented [abstract; Murphey B et al, J Am Soc Nephrol
13:11A, 2002]. Recruited patients had CD4 counts open
face>200 cells/mm3 (mean baseline. 477 ± 38 cells/mm3)
and undetectable viral loads. Patients were required to be
on HAART for at least 6 months prior to renal transplan-
tation. There were 16 cadaveric and seven living-related
transplants. Acute rejection occurred in 34.8% of pa-
tients. An 87% graft survival rate was observed after a
mean follow-up of 378 ± 65.9 days. Follow-up viral loads
were undetectable in 91% of patients, with a mean CD4
count of 497 ± 63 cells/mm3.
In another report, three HIV-1-infected patients with
liver cirrhosis due to chronic hepatitis C virus infection
underwent OTL. A fourth patient developed primary
HIV infection at OTL. Immunosuppressive drugs and
combination antiretroviral therapy were given. The ef-
fects on HIV-1 load, viral diversity and divergence, and
CD4+ T-cell counts, were studied. One patient died af-
ter 3 months. Three subjects were alive after 9 months,
14 months, and 3 years, respectively. In the primary HIV
infection patient, viral load decreased during the sec-
ond week of illness despite immunosuppression. During
the third week, the viremia increased until antiretrovi-
ral treatment was initiated. In all four patients, the HIV-
1 replication was effectively inhibited during follow-up
by the treatment, as determined by undetectable plasma
viremia, lack of viral sequence changes, and increase in
CD4+ T cells. Although a specific HIV-1 immunity is
not necessary to efficiently inhibit the viral replication
when potent antiretroviral therapy is given in liver trans-
plant recipients with primary or chronic HIV-1 infection
[16].
DRUG-DRUG INTERACTIONS IN
HIV-INFECTED SOLID ORGAN TRANSPLANT
RECIPIENT PATIENTS
Drug-drug interactions are becoming an increasingly
important area of research as many new agents become
available. Understanding the drug-drug interactions be-
tween immunosuprresive therapy and HAART will be
critical to patient management. Although immunosup-
pression is required for graft maintenance and effective
antiretroviral therapies are required to suppress HIV
replication, it is unknown how and to what extent the
antirejection therapies will interact with the antiretrovi-
ral medications. Because the use of antiretroviral drugs
has been associated with significant drug-drug interac-
tions [17], caution is required in the management of im-
munosuppressive therapy in these patients. All protease
inhibitors that exhibit anti-HIV activity are metabolized
by the CYP3A4 isoenzyme. In addition, they may also
induce and/or inhibit this enzyme’s activity. Since cy-
closporine, tacrolimus, and sirolimus, the most popular
immunosuppressive therapies, share the same metabolic
pathway, significant drug-drug interactions may oc-
cur when these medications are given concomitantly
(Tables 1 and 2).
Most of the nucleoside reverse transcriptase inhibitors
(NRTIs) are predominantly excreted by the renal system
(tubular secretion) and interactions based upon CYP are
not regularly encountered [18]. The nonnucleoside re-
verse transcriptase inhibitors (NNRTIs) are extensively
metabolized by the liver via the CYP enzyme system
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Table 1. Antiretroviral and immunosuppressive drugs interactions
with cytochrome P450 (CYP) and transporters
Immunosuppressive drugs
CYP Transporters





NNRTIs ABC — —
DLV 3A4, 2D6 P-gp
EFV 3A4, 2D6 P-gp
NVP 3A4 P-gp
Protease inhibitors APV 3A4 P-gp
IDV 3A4 P-gp, MRP
LPV 3A4 P-gp
NFV 3A4 P-gp




Immunosupressive drugs GCs 3A4 P-gp, MRP
AZA — —




Abbreviations are: NRTIs, nucleoside reverse transcriptase inhibitors;
NNRTIs, nonnucleoside reverse transcriptase inhibitors; 3TC, lamivudine; D4T,
stavudine; ddC, zalcitabine; ddI, didanosine; ZDV, zidovudine; ABC, abacavir;
DLV, delavirdine; EFV, efavirenz; NVP, nevirapine; APV, amprenavir; IDV,
indinavir; LPV, lopinavir; NFV, nelfinavir; RTV, ritonavir; SQV, saquinavir;
T20, enfuvirtide; TFV, tenofovir; AZA, azathioprine; CsA, cyclosporine; FK,
tacrolimus; GCs, glucocorticoids; MMF, mycophenolate Mofetil; Siro, sirolimus.
[19]. Besides substrates, nevirapine and efavirenz are
both inducers of CYP3A4, whereas delavirdine acts as
a potent inhibitor of CYP3A4 [20]. In addition, in vitro
studies showed that efavirenz inhibits CYP2C9, 3C19,
and 3A4 (SustivaTM) (Dupont Pharma, Wilmington, DE,
USA). Therefore, drug interactions can be anticipated
if the NNRTIs are coadministered with other drugs that
are metabolized via the same metabolic pathway [21].
CYP3A isoenzymes are predominantly responsible for
the metabolism of protease inhibitors. In addition, all
protease inhibitors are inhibitors of CYP3A. Both ri-
tonavir and lopinavir have also CYP-inducing proper-
ties. Besides being substrates of CYP, protease inhibitors
are also substrates and can act as inhibitors of P-gp, a
transmembrane glycoprotein that functions as an energy-
dependent efflux pump for a wide variety of structurally
unrelated compounds [20, 22, 23]. Furthermore, MRP1
and possibly MRP2 are known to be involved in the dis-
position of the protease inhibitors [22]. These transporter
proteins are also involved in drug efflux. As a result,
since protease inhibitors are potential substrates of P-
gp, MRP1 and MRP2, drug-drug interactions with other
drugs that are transported via the same way are likely to
occur.
Table 2. Potential antiretroviral and immunosuppressive drug-drug
inteactions.
Immunosupressive drugs
GCs AZA CsA FK MMF Siro
NRTIs 3TC NA NA 0 0 + 0
D4T NA NA NA NA NA NA
ddC NA NA 0 0 NA 0
ddI NA NA 0 0 + 0
ZDV NA NA 0 0 − 0
NNRTIs ABC NA NA NA NA + NA
DLV + NA NA NA NA +
EFV − NA − NA NA NA
NVP − NA NA NA NA NA
Protease inhibitors APV − 0 ± ± NA ±
IDV − 0 ± ± NA ±
LPV − 0 ± ± NA +
NFV − 0 ± + NA ±
RTV + 0 ± + NA ±
SQV − 0 + + NA ±
T20 NA NA NA NA NA NA
TFV NA NA NA NA + NA
Abbreviations are: NRTIs, nucleoside reverse transcriptase inhibitors;
NNRTIs, nonnucleoside reverse transcriptase inhibitors; AZA, azathioprine;
CsA, cyclosporine; FK, tacrolimus; GCs, glucocorticoids; MMF, mycophenolate
mofetil; Siro, sirolimus; 3TC, lamivudine; D4T, stavudine; ddC, zalcitabine; ddI,
didanosine; ZDV, zidovudine; ABC, abacavir; DLV, delavirdine; EFV, efavirenz;
NVP, nevirapine; APV, amprenavir; IDV, indinavir; LPV, lopinavir; NFV,
nelfinavir; RTV, ritonavir; SQV, saquinavir; T20, enfuvirtide; TFV, tenofovir; 0,
lack of interaction; +, positive interaction exists (either for the antiretroviral
or the immunosuppressive activities); −, negative interaction exists (either for
the antiretroviral or the immunosuppressive activities); ±, interaction may
theoretically occur.
Glucocorticoids
Glucocorticoids have been proposed for use in HIV
on the basis of their immune modulator properties. Pred-
nisolone treatment, for example, increased CD4 T-cell
count and improved or stabilized immunologic markers
in one study [24]. Corticosteroids are metabolized and
may induce CYP3A4 [25]. They may thus interfere with
comedications that are also substrates of this enzyme.
Furthermore, the gradual decrease in corticosteroid dose
that most patients have may be responsible for the re-
duced oral clearance of tacrolimus over time [26–29].
Coadministration of corticosteroids and antiretroviral
drugs showed an increase in systemic concentration of
corticosteroids by CYP inhibition by delavirdine and pro-
tease inhibitorss. Indeed, CYP3A inhibition by ritonavir
increases prednisolone concentration (Norvir) (Abbott
Laboratories, North Chicago, IL, USA). Moreover, sys-
temic concentration of dexamethasone can be decreased
when coadministerd with efavirenz and nevirapine by
the same pathway inhibition [21]. However, dexam-
ethasone induced CYP3A4 and therefore decreased
plasma concentration of protease inhibitors/NNRTIs.
Dosage modifications of dexamethasone (increased with
efavirenz and nevirapine and decreased with protease in-
hibitors/delavirdine) may therefore be needed in those
patients. In addition, drug and clinical monitoring for
536 Izzedine et al: Antiretroviral and immunosuppressive drug-drug interactions
adapted blood levels and symptoms of hypercorticism are
necessary [21].
Glucocorticoids in HIV-infected transplant recipients
patients will contribute to the exacerbation of oppor-
tunistic infections and to the risk of bone demineraliza-
tion and acute vascular necrosis of the femoral head.
Cyclosporine, tacrolimus, and sirolimus
Cyclosporine. Cyclosporine is primarily metabolized
in the liver by CYP3A. Furthermore, it is a substrate for
P-gp and MRP2 transporters. HIV protease inhibitors
inhibit CYP3A and are substrates and/or potential in-
hibitors/inducers of P-gp and MRP. They thus may induce
increased cyclosporine levels due to metabolism or active
transport alterations.
Mechanisms of action. The strong activity cyclospor-
ine A in suppressing T-cell activation is achieved through
the formation of a cyclosporine A-cyclophilin A complex
that inhibits the calcium- and calmoduline-dependent
protein phosphatase calcineurin. Interestingly, beyond
the hypothesis that cyclosporine could indirectly suppress
HIV replication by affecting T-cell activation, it has been
discovered that cyclosporine was directly active against
HIV, independently of its immunosuppressive effects. In
fact, the natural partner of cyclosporine, cyclophilin A, is
one of the postulated cellular factors playing a key role
in HIV infection. Actually, cyclophilin A is recruited in
stoichiometric amounts in the nascent HIV-1 virion to
interact with HIV-1 gag polyprotein [30]. This process is
required for final HIV virion maturation [31]. Chronically
infected cells produce noninfectious HIV particles in the
presence of cyclosporine A [32]. In addition, analogues
of cyclosporine A, lacking immunosuppressive nature but
retaining affinity for cyclophilin A, are able to decrease or
abolish HIV infectivity in vitro [33, 34]. Furthermore, it
can be postulated that cyclosporine A may improve pro-
tease inhibitors’ absorption. In fact, it has been shown in
vitro that saquinavir, ritonavir, and indinavir were sub-
strates of a cellular efflux mechanism mediated by the
human P-gp [35, 36]. Cyclosporine, which inhibits P-gp, is
able to reverse the countertransport of those three drugs,
possibly favoring their oral absorption and their net in-
tracellular accumulation which are modulated by such
mechanisms.
Clinical experience. Despite the highly specific an-
tiviral action of cyclosporine A in vitro, only few and
somewhat conflicting in vivo studies are currently avail-
able. In one study, cyclosporine A was administered
alone to HIV patients at various stages of the disease
(patients with AIDS and HIV+ patients without AIDS
with T-cell count from 300 to 600/lL or <300/lL). Cy-
closporine contributed to a lowering of CD8 T-cell count
in most patients and to a significant increase in CD4
T-cell count in the non-AIDS subgroup [37]. In a follow-
up of a study by Levy et al [38] (median duration of
11 months), none of the asymptomatic patients treated
with cyclosporine A progressed to AIDS and the mean
CD4 T-cell count remained unchanged. Cyclosporine
had no significant impact on the evolution of total lym-
phocyte count, CD8 T-cell count, and p24 antigenemia.
In contrast, another report indicates that patients with
AIDS experienced severe toxicity with cyclosporine A
treatment [39]. Four case reports and a review of the
literature report that the incidence of AIDS was signifi-
cantly lower in HIV+ transplant recipients receiving an
immunosuppressive regimen, including cyclosporine A,
than in patients managed with cyclosporine A-free reg-
imens [40]. This was in contrast with a previously pub-
lished study in which HIV+ transplanted patients treated
with cyclosporine A progressed more rapidly to AIDS
than HIV+ individuals not receiving cyclosporine A
[41].
However, recent evidence suggests that the addition
of cyclosporine A to HAART may offer beneficial long-
term effects to HIV-infected patients. In an open-label,
prospective study involving nine HIV-infected patients
with an early stage of infection (mean CD4 counts of
527 ± 77 cells/L), cyclosporine A was used during the first
8 weeks of treatment with HAART (stavudine, lamivu-
dine, nelfinavir, and saquinavir). This regimen resulted
in a rapid restoration of CD4 cells in the absence of a
simultaneous increase in total T-cell production (within
7 days) [42]. The calcineurin inhibitors, cyclosporine A
and tacrolimus, have further been shown to inhibit HIV-
1 DNA nuclear import and replication in vitro [43, 44].
Binding of HIV-1 p24 (gag) to cyclophilin A, the pre-
dominant cellular receptor protein of cyclosporines, is
required for HIV nuclear import [45, 46]. Cyclophilin A
also binds to nongag-encoded proteins, such as p17, Nef,
Vif, and gp-120. Billich et al [46] using a cyclosporine A
analogue (SDZ NIM 811), blocked the formation of the
cyclophilin A-HIV-1 p24 gag complex. The NFAT fam-
ily of transcription factors has been suggested as a po-
tential therapeutic target for the calcineurin inhibitors.
Cron et al [43] examined the role of NFAT1, the pre-
dominant NFAT expressed in primary human peripheral
CD4 T cells, in HIV-1 transcription and p24 (gag) pro-
duction in vitro. Increasing NFAT1 and NFAT2 within
primary human peripheral blood CD4 T cells infected
with an HIV-1 provirus increased HIV-1 LTR transcrip-
tion and p24 (gag) expression. Furthermore, the addition
of either cyclosporine A or tacrolimus inhibited such ac-
tivity. However, the long-term effect of calcineurin in-
hibitors on patient survival, HIV-1 viral replication, and
disease progression is not known, and remains to be stud-
ied in randomized controlled trials in patients with renal
disease.
Another study further indicated that cyclosporine
A may exhibit an intrinsic carcinogenic potential [47].
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Indeed, the drug induced in vitro morphologic and be-
havioral alterations that facilitated the transformation of
a noninvasive tumoral phenotype into invasive. More-
over, in the SCID-beige mouse model, cyclosporine A–
enhanced tumor cells invasive and metastatic growth [47].
Both effects were mediated by cyclosporine A–induced
production of tumor growth factor-b , which is also known
to be a potent immunosuppressor.
Pharmacokinetic interactions. A drug-drug interac-
tion between saquinavir and cyclosporine A has been re-
ported once. In this patient, cyclosporine A trough levels
were stable at a dosage of 150 mg twice daily (levels within
the range of 150 to 200 lg/L). Within 3 days after starting
saquinavir therapy at a dosage of 1200 mg three times a
day, the patient reported fatigue, headache, and gastroin-
testinal discomfort. At this time, cyclosporine A trough
levels had tripled to 580 lg/L. After cyclosporine A and
saquinavir dosages were decreased to 75 mg twice daily
and 600 mg three times a day, respectively, the symptoms
subsided. Time curve analysis showed that the area under
the concentration time curve (AUC0−12) observed with
75 mg cyclosporine A during treatment with saquinavir
was 90% the AUC0−12 seen with 150 mg cyclosporine A
alone. Meanwhile, saquinavir showed an AUC0−12 4.3-
fold higher than the average value of five control pa-
tients receiving saquinavir 600 mg twice daily without
cyclosporine A and 11.1-fold higher than the AUC0−12 re-
ported in the literature (0.47 hour per mg/L) [48, 49]. This
interaction is most likely due to the similar metabolism
of both drugs via CYP3A4. An additional explanation
might be that both drugs also exhibit a high affinity for
P-gp [50].
In two case reports, coadministration of NNRTI
(efavirenz 600 mg four times a day + cyclosporine A
175 mg twice a day) or protease inhibitors (saquinavir
1200 mg three times a day + cyclosporine A 150 mg
four times a day) reduced cyclosporine A concentration
(75%) 1 month after efavirenz started [51], or increased
cyclosporine A concentration threefold [52] by similar
metabolism via induction CYP3A4 and P-gp. Therefore,
increased absorption or decreased clearance of the asso-
ciated drug may occur, as recently postulated by other
authors [53, 54].
Tacrolimus. Tacrolimus is a macrolide lactone that is
primarily metabolized in the liver by CYP3A. Although
potential drug-drug interactions are numerous, only a few
have been characterized. HIV protease inhibitors inhibit
CYP3A and may thus induce increased tacrolimus levels
due to metabolism alterations (ritonavir) (Abbott Labo-
ratories) [55].
Mechanisms of action. Tacrolimus mechanism of ac-
tion is similar to that of cyclosporine A, involving the
formation of immunophilin complex. Tacrolimus binds
to FK 506 binding protein 12 and the immunophilin-drug
complex then interacts with calcineurin, leading to in-
hibition of early steps of T-cell activation. Other effects
probably contribute to the overall pharmacodynamic ef-
fect of tacrolimus as well, but it is unclear to what extent
[56, 57]. Increased tacrolimus toxicity is observed with in-
creased tacrolimus concentrations. Several HIV protease
inhibitors are known to inhibit the CYP3A4 enzyme sys-
tem. For both cyclosporine A and tacrolimus [58–60] se-
vere toxicity has been described due to combined treat-
ment with such protease inhibitors [61].
Clinical experience. The main study in this field in-
cluded seven liver transplant patients (six males and 1 fe-
male) and four male kidney transplant patients infected
with HIV who underwent surgery between September
1997 and January 2001. Initial immunosuppression con-
sisted of tacrolimus and steroids for liver transplant
patients or tacrolimus, steroids, and MMF for kidney
transplant recipients. Their current baseline immunosup-
pression and HAART regimen were examined retrospec-
tively. Of the seven liver recipients, one died 2 weeks after
liver transplant and never received posttransplantation
HAART therapy. The remaining six patients were placed
on a regimen consisting of two NRTIs and one protease
inhibitor (nelfinavir in five and indinavir in one) based on
known viral sensitivities or history of a previous clinical
response. Kidney recipients received NRTIs and NNRTIs
but no protease inhibitors. The mean tacrolimus dose in
liver transplant was 0.6 mg/day, with mean trough concen-
trations of 9.7 mg/mL. Compared with historic controls
(liver transplant patients not on HAART), the average
tacrolimus dose was 16-fold lower in patients on HAART.
In contrast to liver transplant, HIV+ kidney transplant
not on protease inhibitor therapy required a higher mean
tacrolimus dose (9.5 mg/day) to achieve similar trough
concentrations (9.6 mg/mL). When patients on nelfinavir
alone (N = 5) were compared with a control group not
on antiretroviral therapy, the need for a tacrolimus dose
was 38 times lower (mean dose, 0.26 mg/day). The in-
teraction thus seemed to be more pronounced with the
use of nelfinavir as opposed to indinavir, although fur-
ther experience is required to confirm this observation. In
contrast, HAART using NRTIs and NNRTIs without the
protease inhibitors, as shown in kidney transplants, pro-
duced less significant effects on tacrolimus metabolism.
Caution and frequent drug level monitoring are therefore
necessary when HAART is introduced or withdrawn in
HIV+ solid organ transplant recipients [62].
It is also important to realize that some protease in-
hibitors act both as inducers and inhibitors of CYP3A4.
However, when coadministered, their inhibitory effect
predominates. Jain et al [62, 63] recommended at least
a fourfold reduction in tacrolimus doses when nelfinavir
is introduced, and a twice-a-week trough concentrations
follow-up for further dosage adjustment. Conversely, it is
mandatory to increase tacrolimus dosage when protease
inhibitors are withheld.
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Pharmacokinetic interactions. Tacrolimus is primar-
ily metabolized in the liver, and to lesser extent in the gut
[64]. Less than 1% is excreted unchanged in urine and
its hepatic metabolism is mediated by the CYP3A en-
zyme system. Metabolites are secondary excreted in the
bile. However, protease inhibitors have been suggested to
alter tacrolimus pharmacokinetics, clinical toxicity from
ritonavir-tacrolimus combination has not been reported
to date although tacrolimus levels were increased by
three (nelfinavin) (Agouron Pharmaceuticals, Inc., La
Jolla, CA, USA). Nevertheless, combination therapy with
saquinavir and ritonavir may lead to a noticeable increase
in tacrolimus levels (>120 ng/mL) with a long time before
normalization of tacrolimus levels of more than 10 days.
Although nelfinavir is a lower CYP3A inhibitor than
ritonavir [1], initiation of treatment with nelfinavir ne-
cessitated in some cases a drastic reduction in tacrolimus
dosage, from 4 mg twice daily to 0.5 mg every 3 to 5 days.
Currently, nelfinavir package insert does not specifically
describe this interaction.
The nucleoside analogues stavudine, lamivudine, and
didanosine are primarily excreted through the kidney [37]
and are thus unlikely to increase tacrolimus levels. Fur-
thermore, tacrolimus may also inhibit the CYP3A en-
zyme system [37] thereby increasing levels of other drugs
such as protease inhibitors. Moreover, in two others case
reports, coadministration of protease inhibitors (nelfi-
navir 500 mg three times a day, or ritonavir/saquinavir
400/400 mg twice a day) increased tacrolimus and nelfi-
navir [60] concentrations.
Sirolimus.
Mechanisms of action. Interest in sirolimus as an im-
munosuppressive therapy in organ transplantation de-
rives from its unique mechanism of action, its unique
side-effect profile, and its ability to synergize with other
immunosuppressive agents. Sirolimus forms an immuno-
suppressive complex with intracellular protein, FKBP12.
This complex blocks the activation of the cell-cycle-
specific kinase, target of rapamycin (TOR). The down-
stream events that follow the inactivation of TOR result
in the blockage of cell-cycle progression at the juncture
of G1 and S phase. Furthermore, sirolimus is a substrate
for CYP3A4/5 and P-gp [65, 66].
Clinical experience and pharmacokinetic interactions.
In one report, even with one fifth the recommended
nelfinavir dose, there was a significant increase in
sirolimus blood concentrations in one patient as com-
pared with three other patients who were not receiv-
ing nelfinavir [54]. Furthermore, protease inhibitors/
delavirdine inhibited CYP3A and increased sirolimus
and plasma concentration (Agenerase (GlaxoWell-
come, Research Triangle Park, NC, USA) (KaletraTM)
(Abbott Laboratories). Therefore, therapeutic drug mon-
itoring sirolimus/protease inhibitors/NNRTIs are recom-
mended.
Azathioprine and MMF
Azathioprine has been associated with exacerba-
tion of HIV replication [Lang PH, Seminaires d’Uro-
Nephrologie, Pitie-Salpetriere, XXIXeme serie 2003: 63–
69]. By contrast, MMF has been shown to reduce HIV
replication in vitro [67, 68]. Furthermore, azathioprine
being metabolized by tissue and plasmatic enzymes, hep-
atic metabolic interactions are unlikely to occur with an-
tiretroviral drugs [69].
MMF is the ester prodrug of mycophenolic acid
(MPA). It is currently approved for use in the prophy-
laxis of renal allograft rejection and is widely used in
solid organ transplantation. MPA reversibly inhibits in-
osine monophosphate dehydrogenase (IMPDH), thus
limiting the rate of de novo synthesis of guanosine nu-
cleotides [70]. Unlike other cell lineages, the purine syn-
thesis salvage pathway is inefficient in lymphocytes and
monocytes. These cells therefore require de novo synthe-
sis to support proliferation [71]. Through inhibition of
IMPDH, MPA thus selectively inhibits lymphocyte and
monocyte proliferation. Furthermore, stimulated lym-
phocytes possess an isoform of IMPDH that is four times
more sensitive to MPA than the predominant isoform in
nonstimulated lymphocytes [72]. In vitro, MMF also has
a synergistic anti-HIV-1 activity in combination with aba-
cavir, an NRTI. It has been observed that MMF enhanced
abacavir susceptibility of HIV isolates, which were resis-
tant to multiple antiretroviral agents. These effects were
attributed to the effect of both agents on intracellular
guanosine metabolism: abacavir via its carbovir triphos-
phate metabolite guanosine analogue and MMF via inhi-
bition of IMPDH. By contrast, MMF seems to antagonize
the antiviral effects of zidovudine and stavudine [73].
Abacavir is the first clinically available guanosine ana-
logue that inhibits HIV-1 reverse transcriptase. It is the
most potent nucleoside analogue available to date. The
combination of abacavir and MPA to inhibit HIV repli-
cation in cultured peripheral blood mononuclear cells
(PBMCs) is exceedingly potent and synergistic [67]. Low
MPA concentrations greatly enhance the antiviral activ-
ity of abacavir in both activated PBMCs and monocyte-
derived macrophages (MDMs). The combination of MPA
and abacavir potently inhibited HIV from carrying the
MI184V mutation. This mutation, frequent in the large
patient population with significant antiretroviral experi-
ence, engenders low-level resistance to abacavir in vitro
[74] [abstract 134; Lanier R, et al, presented at the 6th
Conference on Retrovirus and Opportunistic Infections,
Chicago, 1999] but its presence in isolation does not ap-
pear to impair response to abacavir therapy in clinical
trials. These in vitro findings however necessitate clinical
investigations to be confirmed. However, the use of MPA
with other antiretrovirals must be carefully considered.
Indeed, the concomitant use of thymidine analogues, such
Izzedine et al: Antiretroviral and immunosuppressive drug-drug interactions 539
as zidovudine or stavudine, should be avoided because of
the antagonism between MPA and these agents. Further-
more, to a lesser extent, the activities of didanosineand
tenofovir also seem to be enhanced by MPA [67, 73, 75].
In an open-label pilot study in which MMF 250 mg
twice daily was added to the antiretroviral therapy of
seven patients with late-stage AIDS who had failed eight
or more antiretroviral regimens, CD4+ T-cell counts
did not change significantly: from 117 cells/lL at en-
try to 139 cells/lL at 24 weeks of therapy. Median HIV
RNA was 4.78 log10 copies/mL at entry. Declines in vi-
ral load (>0.5 log10 copies/mL) were seen in four of five
subjects. Median changes were 0.15 log10 copies/mL at
24 weeks. Trough MPA plasma levels ranged from 0.26 to
1.67 lg/mL; peak levels 90 minutes after dosing from 1.20
to 1.77 lg/mL. MMF’s AUC was between 20 and 29.1 lg
∗ hour/mL from week 16 to week 32 but only 9.8 lg ∗
hour/mL at week 2. Therapy was generally well tolerated
and no toxicity attributable to MMF was noted during the
study period. At a dosage of 500 mg twice daily, MMF in-
duced a viral load decline of up to 1.09 log10 copies/mL.
This effect was often transient, but persisted until up to
64 weeks in some subjects. Declines in viral load and
measurable changes in the carbovin triphosphate (CBV)-
TP/deoxyguanosine triphosphate (dGTP) ratio thus ap-
pear achievable with MPA’s AUC below the 30 to 60 lg ×
hour/mL range usually targeted in organ transplantation
[76].
Muromonab-CD3
The use of antilymphocyte antibodies has been asso-
ciated with severe exacerbation of HIV replication. The
alloimmune response is one of the strongest stimuli for
the activation of latent retroviral and herpes virus in-
fections. Thus, antilymphocyte antibodies activate HIV,
cytomegalovirus, and Epstein-Barr virus. Infections with
these viruses will enhance the likelihood of additional op-
portunistic infections via the global immune suppression
produced by these agents [77]. However, no mention is
made of any drug-drug interaction between antiretroviral
drugs and muromonab-CD3.
PROPOSITION
With respect to those clinical and pharmacologic find-
ings, the best therapeutic choice which seems to be ef-
fective and safe in HIV-infected patients undergoing
solid organ transplantation is abacavir and didanosine
for antiretroviral therapy and glucocorticoids, MMF, and
tacrolimus or rapamycin (sirolimus) as the immunosup-
pressive drug. These combinations induce no or at least
less drug-drug interactions than others. Furthermore,
some of these combinations have been suggested to be
beneficial for the patient. For example, abacavir and
MMF are synergystic when used in combination therapy
to treat HIV infection. Those patients should be systemat-
ically carefully monitored. To our opinion, reducing the
HIV viral load and ensuring an adequate immunosup-
pression to avoid any graft rejection should be consid-
ered equally. This will necessitate a close collaboration
between specialists of the fields involved: transplantation,
infectious diseases, and pharmacology.
CONCLUSION
Because organ transplant in HIV+ patients is in its
nascent stage, describing the long-term pharmacokinetic
and pharmacodynamic profiles of concomitant immuno-
suppressive and antiretroviral agents in HIV+ transplant
recipients will be essential. Careful monitoring for inter-
actions between immunosuppressant drugs and anti-HIV
medication is required in order to ensure that effective
therapy for both HIV and rejection is sustained. Multi-
disciplinary team evaluating and caring for these patients
must include specialists with expertise in HIV, transplan-
tation, and pharmacology.
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